Publication

Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice

Zeevat, F., van der Schans, J., Boersma, W. G., Boersma, C. & Postma, M. J., Oct-2019, In : Vaccine. 37, 43, p. 6282-6284

Research output: Contribution to journalArticleAcademicpeer-review

APA

Zeevat, F., van der Schans, J., Boersma, W. G., Boersma, C., & Postma, M. J. (2019). Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine, 37(43), 6282-6284. https://doi.org/10.1016/j.vaccine.2019.08.051

Author

Zeevat, F ; van der Schans, J ; Boersma, W G ; Boersma, C ; Postma, M J. / Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands : Challenging the Dutch Health Council's advice. In: Vaccine. 2019 ; Vol. 37, No. 43. pp. 6282-6284.

Harvard

Zeevat, F, van der Schans, J, Boersma, WG, Boersma, C & Postma, MJ 2019, 'Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice', Vaccine, vol. 37, no. 43, pp. 6282-6284. https://doi.org/10.1016/j.vaccine.2019.08.051

Standard

Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands : Challenging the Dutch Health Council's advice. / Zeevat, F; van der Schans, J; Boersma, W G; Boersma, C; Postma, M J.

In: Vaccine, Vol. 37, No. 43, 10.2019, p. 6282-6284.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Zeevat F, van der Schans J, Boersma WG, Boersma C, Postma MJ. Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice. Vaccine. 2019 Oct;37(43):6282-6284. https://doi.org/10.1016/j.vaccine.2019.08.051


BibTeX

@article{dceee5ae619d46e5a3a381cf65922a1e,
title = "Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: Challenging the Dutch Health Council's advice",
abstract = "Recently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conventional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for the conjugated vaccine. We argue that using the same data and methods as presented by the Health Council, a different perspective on the results leads to a conclusion that not only the polysaccharide but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness modelling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the conjugated vaccine seems cost-effective; i.e. well below the threshold of €20,000 per quality-adjusted life year, reflecting the most stringent threshold used for vaccines in the Netherlands.",
author = "F Zeevat and {van der Schans}, J and Boersma, {W G} and C Boersma and Postma, {M J}",
note = "Copyright {\circledC} 2019. Published by Elsevier Ltd.",
year = "2019",
month = "10",
doi = "10.1016/j.vaccine.2019.08.051",
language = "English",
volume = "37",
pages = "6282--6284",
journal = "Vaccine",
issn = "0264-410X",
publisher = "ELSEVIER SCI LTD",
number = "43",

}

RIS

TY - JOUR

T1 - Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands

T2 - Challenging the Dutch Health Council's advice

AU - Zeevat, F

AU - van der Schans, J

AU - Boersma, W G

AU - Boersma, C

AU - Postma, M J

N1 - Copyright © 2019. Published by Elsevier Ltd.

PY - 2019/10

Y1 - 2019/10

N2 - Recently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conventional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for the conjugated vaccine. We argue that using the same data and methods as presented by the Health Council, a different perspective on the results leads to a conclusion that not only the polysaccharide but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness modelling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the conjugated vaccine seems cost-effective; i.e. well below the threshold of €20,000 per quality-adjusted life year, reflecting the most stringent threshold used for vaccines in the Netherlands.

AB - Recently, the Dutch Health Council advised on elderly pneumococcal vaccination favouring the conventional polysaccharide vaccine over the novel conjugated vaccine. This advice was strongly inspired by a cost-effectiveness analysis considered to show favourable outcomes for the polysaccharide but not for the conjugated vaccine. We argue that using the same data and methods as presented by the Health Council, a different perspective on the results leads to a conclusion that not only the polysaccharide but also the conjugated pneumococcal vaccine is cost-effective. Our alternative perspective concerns the use of realistic vaccine prices, and applying an adequate time horizon for cost-effectiveness modelling. Notably, for one-off vaccination of 65-years old elderly, in all investigated analyses, also the conjugated vaccine seems cost-effective; i.e. well below the threshold of €20,000 per quality-adjusted life year, reflecting the most stringent threshold used for vaccines in the Netherlands.

U2 - 10.1016/j.vaccine.2019.08.051

DO - 10.1016/j.vaccine.2019.08.051

M3 - Article

VL - 37

SP - 6282

EP - 6284

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 43

ER -

ID: 96876993